Facebook Twitter Linkedin NASDAQ Market NewsClick here to email authorNEXT STORYAzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference (January 13) in San FranciscoPREV STORYT2 Biosystems Appoints Industry Veteran John Sperzel as Chief Executive Officer